Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism

Kara E. Hayford, Christi Ann Patten, Teresa A. Rummans, Darrell R. Schroeder, Kenneth P. Offord, Ivana T Croghan, Elbert D. Glover, David P L Sachs, Richard D. Hurt

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Background: A past history of major depression or alcoholism has been associated with poorer smoking treatment outcomes. Aim: To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence. Method: Data were drawn from a multicentre trial of bupropion for smoking cessation. Smokers (n = 615) received placebo or bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD). The primary outcome was the point prevalence smoking abstinence at the end of treatment and at one year. The Beck Depression Inventory (BDI) was used to assess depressive symptoms. Results: A significant dose-response effect of bupropion for smoking cessation was found. This was independent of history of major depression or alcoholism. Among those continuously abstinent from smoking for two weeks following TQD, an increase in BDI score was associated with a return to smoking at end of treatment. Conclusions: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism. Increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking. Declaration of interest: Supported by a grant from Glaxo Wellcome Inc.

Original languageEnglish (US)
Pages (from-to)173-178
Number of pages6
JournalBritish Journal of Psychiatry
Volume174
Issue numberFEB.
StatePublished - 1999

Fingerprint

Bupropion
Smoking Cessation
Alcoholism
Depression
Smoking
Equipment and Supplies
Organized Financing
Multicenter Studies
Placebos

ASJC Scopus subject areas

  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. / Hayford, Kara E.; Patten, Christi Ann; Rummans, Teresa A.; Schroeder, Darrell R.; Offord, Kenneth P.; Croghan, Ivana T; Glover, Elbert D.; Sachs, David P L; Hurt, Richard D.

In: British Journal of Psychiatry, Vol. 174, No. FEB., 1999, p. 173-178.

Research output: Contribution to journalArticle

Hayford, KE, Patten, CA, Rummans, TA, Schroeder, DR, Offord, KP, Croghan, IT, Glover, ED, Sachs, DPL & Hurt, RD 1999, 'Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism', British Journal of Psychiatry, vol. 174, no. FEB., pp. 173-178.
Hayford, Kara E. ; Patten, Christi Ann ; Rummans, Teresa A. ; Schroeder, Darrell R. ; Offord, Kenneth P. ; Croghan, Ivana T ; Glover, Elbert D. ; Sachs, David P L ; Hurt, Richard D. / Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. In: British Journal of Psychiatry. 1999 ; Vol. 174, No. FEB. pp. 173-178.
@article{0b4892c0abed49b2b06317f7dd329fc0,
title = "Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism",
abstract = "Background: A past history of major depression or alcoholism has been associated with poorer smoking treatment outcomes. Aim: To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence. Method: Data were drawn from a multicentre trial of bupropion for smoking cessation. Smokers (n = 615) received placebo or bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD). The primary outcome was the point prevalence smoking abstinence at the end of treatment and at one year. The Beck Depression Inventory (BDI) was used to assess depressive symptoms. Results: A significant dose-response effect of bupropion for smoking cessation was found. This was independent of history of major depression or alcoholism. Among those continuously abstinent from smoking for two weeks following TQD, an increase in BDI score was associated with a return to smoking at end of treatment. Conclusions: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism. Increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking. Declaration of interest: Supported by a grant from Glaxo Wellcome Inc.",
author = "Hayford, {Kara E.} and Patten, {Christi Ann} and Rummans, {Teresa A.} and Schroeder, {Darrell R.} and Offord, {Kenneth P.} and Croghan, {Ivana T} and Glover, {Elbert D.} and Sachs, {David P L} and Hurt, {Richard D.}",
year = "1999",
language = "English (US)",
volume = "174",
pages = "173--178",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "FEB.",

}

TY - JOUR

T1 - Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism

AU - Hayford, Kara E.

AU - Patten, Christi Ann

AU - Rummans, Teresa A.

AU - Schroeder, Darrell R.

AU - Offord, Kenneth P.

AU - Croghan, Ivana T

AU - Glover, Elbert D.

AU - Sachs, David P L

AU - Hurt, Richard D.

PY - 1999

Y1 - 1999

N2 - Background: A past history of major depression or alcoholism has been associated with poorer smoking treatment outcomes. Aim: To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence. Method: Data were drawn from a multicentre trial of bupropion for smoking cessation. Smokers (n = 615) received placebo or bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD). The primary outcome was the point prevalence smoking abstinence at the end of treatment and at one year. The Beck Depression Inventory (BDI) was used to assess depressive symptoms. Results: A significant dose-response effect of bupropion for smoking cessation was found. This was independent of history of major depression or alcoholism. Among those continuously abstinent from smoking for two weeks following TQD, an increase in BDI score was associated with a return to smoking at end of treatment. Conclusions: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism. Increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking. Declaration of interest: Supported by a grant from Glaxo Wellcome Inc.

AB - Background: A past history of major depression or alcoholism has been associated with poorer smoking treatment outcomes. Aim: To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence. Method: Data were drawn from a multicentre trial of bupropion for smoking cessation. Smokers (n = 615) received placebo or bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD). The primary outcome was the point prevalence smoking abstinence at the end of treatment and at one year. The Beck Depression Inventory (BDI) was used to assess depressive symptoms. Results: A significant dose-response effect of bupropion for smoking cessation was found. This was independent of history of major depression or alcoholism. Among those continuously abstinent from smoking for two weeks following TQD, an increase in BDI score was associated with a return to smoking at end of treatment. Conclusions: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism. Increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking. Declaration of interest: Supported by a grant from Glaxo Wellcome Inc.

UR - http://www.scopus.com/inward/record.url?scp=0032990521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032990521&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 173

EP - 178

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - FEB.

ER -